Consolidation and Maintenance Therapy for Multiple Myeloma After Autologous Transplantation: Where Do We Stand?

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2015 Apr 21

PMID 25893452

Citations 18

Authors

M Mohty

P G Richardson

P L McCarthy

M Attal

Affiliations

Soon will be listed here.

Abstract

Novel agents including proteasome inhibitors and immunomodulatory drugs are now routinely utilized as part of the induction regimen before transplantation and this has resulted in substantial improvements in the depth of response achieved before transplant. Given that depth of response is prognostic for overall outcome, a number of studies have been conducted or are ongoing to investigate the use of novel agents as consolidation and maintenance therapy after transplant. Most clinical trials have reported after consolidation and maintenance therapy an increased PFS and even overall survival in some of them. The use of post-autologous stem cell transplant consolidation and maintenance is an increasingly attractive concept. However, some side effects could be observed with such long-term therapy and many open questions are still under debate. The decision to administer consolidation and/or maintenance therapy will likely need to be guided by the individual patient situation. This review aims to analyze the currently available research evidence in this field.

Citing Articles

Boquoi A, Giagounidis A, Goldschmidt H, Heinsch M, Rummel M, Kroger N Cancers (Basel). 2023; 15(21).

PMID: 37958331 PMC: 10650513. DOI: 10.3390/cancers15215157.

Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma.

Benjamin C, Desai S, Pereira D, Beitinjaneh A, Jimenez A, Goodman M Transfus Apher Sci. 2023; 62(5):103731.

PMID: 37236900 PMC: 10657907. DOI: 10.1016/j.transci.2023.103731.

Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation.

Vu M, Kieu T, Vu H Leuk Res Rep. 2023; 19:100368.

PMID: 37090842 PMC: 10119789. DOI: 10.1016/j.lrr.2023.100368.

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.

Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied N Haematologica. 2022; 108(4):1105-1114.

PMID: 35770529 PMC: 10071135. DOI: 10.3324/haematol.2021.280568.

Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T J Cancer Res Clin Oncol. 2021; 148(1):191-203.

PMID: 34080068 DOI: 10.1007/s00432-021-03668-6.

References

Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L . Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010; 28(12):2077-84. DOI: 10.1200/JCO.2009.23.7172. View

Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L . Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du.... J Clin Oncol. 2014; 32(25):2712-7. DOI: 10.1200/JCO.2013.54.8164. View

Kagoya Y, Nannya Y, Kurokawa M . Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res. 2012; 36(8):1016-21. DOI: 10.1016/j.leukres.2012.04.001. View

Cavo M, Pantani L, Petrucci M, Patriarca F, Zamagni E, Donnarumma D . Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120(1):9-19. DOI: 10.1182/blood-2012-02-408898. View

Barlogie B, Anaissie E, Haessler J, Van Rhee F, Pineda-Roman M, Hollmig K . Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008; 113(2):355-9. DOI: 10.1002/cncr.23546. View

Morgan G, Davies F, Gregory W, Bell S, Szubert A, Navarro Coy N . Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2011; 97(3):442-50. PMC: 3291601. DOI: 10.3324/haematol.2011.043372. View

Cavo M, Tacchetti P, Patriarca F, Petrucci M, Pantani L, Galli M . Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised.... Lancet. 2010; 376(9758):2075-85. DOI: 10.1016/S0140-6736(10)61424-9. View

Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta J, Cavo M . Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013; 31(26):3279-87. DOI: 10.1200/JCO.2012.48.4626. View

Sonneveld P, Schmidt-Wolf I, van der Holt B, El Jarari L, Bertsch U, Salwender H . Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012; 30(24):2946-55. DOI: 10.1200/JCO.2011.39.6820. View

10.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M . Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12(5):431-40. DOI: 10.1016/S1470-2045(11)70081-X. View

11.

Barlogie B, Anaissie E, van Rhee F, Shaughnessy Jr J, Szymonifka J, Hoering A . Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol. 2010; 28(18):3023-7. PMC: 2903335. DOI: 10.1200/JCO.2009.26.4465. View

12.

Maiolino A, Hungria V, Garnica M, Oliveira-Duarte G, Oliveira L, Mercante D . Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol. 2012; 87(10):948-52. DOI: 10.1002/ajh.23274. View

13.

Attal M, Harousseau J, Leyvraz S, Doyen C, Hulin C, Benboubker L . Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108(10):3289-94. DOI: 10.1182/blood-2006-05-022962. View

14.

McCarthy P, Owzar K, Hofmeister C, Hurd D, Hassoun H, Richardson P . Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1770-81. PMC: 3744390. DOI: 10.1056/NEJMoa1114083. View

15.

Nooka A, Kaufman J, Behera M, Langston A, Waller E, Flowers C . Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer. 2013; 119(23):4119-28. DOI: 10.1002/cncr.28325. View

16.

Fouquet G, Hebraud B, Garciaz S, Stoppa A, Roussel M, Caillot D . Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation. J Cancer. 2014; 5(3):248-52. PMC: 3963082. DOI: 10.7150/jca.8541. View

17.

Mellqvist U, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K . Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013; 121(23):4647-54. PMC: 3674665. DOI: 10.1182/blood-2012-11-464503. View

18.

Morgan G, Gregory W, Davies F, Bell S, Szubert A, Brown J . The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2011; 119(1):7-15. DOI: 10.1182/blood-2011-06-357038. View

19.

Palumbo A, Bringhen S, Kumar S, Lupparelli G, Usmani S, Waage A . Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014; 15(3):333-42. DOI: 10.1016/S1470-2045(13)70609-0. View

20.

Munshi N, Anderson K . Minimal residual disease in multiple myeloma. J Clin Oncol. 2013; 31(20):2523-6. PMC: 5321086. DOI: 10.1200/JCO.2013.49.2124. View